November 8, 2014
Notes: Dixit, Shreya
Australas J Dermatol. 2013 Nov;54(4):273-6. doi: 10.1111/ajd.12057. Epub 2013 Apr 26.
Author Address: Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Reference Type: Journal Article
Record Number: 4349Author: Dosekun, O., Farrugia, P., Lewis, F. and Sethi, G.
Title: Vulval disease in HIV-positive women attending a tertiary vulval dermatology clinic over a five-year period
Journal: Int J STD AIDS
Short Title: Vulval disease in HIV-positive women attending a tertiary vulval dermatology clinic over a five-year period
Alternate Journal: International journal of STD & AIDS
ISSN: 1758-1052 (Electronic)
Accession Number: 23970605
Antineoplastic Agents/therapeutic use
CD4 Lymphocyte Count
Carcinoma, Squamous Cell/etiology/therapy
Cervical Intraepithelial Neoplasia/*diagnosis/drug therapy/pathology
HIV Infections/*complications/drug therapy/virology
Uterine Cervical Neoplasms/*diagnosis/drug therapy/pathology
Vulvar Diseases/drug therapy/*etiology/microbiology
Abstract: There is a paucity of data on vulval disease in HIV-infected women. We describe the spectrum of vulval disease in HIV-infected women attending a tertiary vulval dermatology referral centre over a five-year period. Seven vulval conditions were identified in 14 women. Most were attending for HIV care (n = 12, 86%), and on combined antiretroviral therapy (CART) with a CD4 cell count above 200 cells/microL (n = 9, 64%) at diagnosis. Imiquimod therapy was effective in treating undifferentiated vulval intraepithelial neoplasia (uVIN) – the most common diagnosis. There were no cases of invasive vulval carcinoma. Hypertrophic herpes simplex virus occurred in one woman stable on CART with good immune reconstitution. Clinicians should be vigilant about the spectrum of vulval disease in HIV-infected women and consider genital examination as part of routine care.